目的 :比较尼立苏和尼莫通治疗脑梗塞的疗效及不良反应。方法 :70例脑梗塞患者随机分为 2组。尼立苏组 34例 ,用尼立苏注射液 10mg ,静滴 ,qd ;尼莫通组 36例 ,用尼莫通注射液 10mg ,静滴 ,qd。两组疗程均为 2周。结果 :治疗后d14尼立苏和尼莫通的有效率分别为 88 2 4%和 83 33% ,不良反应率分别为 14 7%和 13 88% ,均无显著性差异 (P >0 .0 5 ) ;两组的功能改善程度比较也无显著性差异 (P >0 .0 5 )。结论 :尼立苏是治疗脑梗塞的安全、有效的药物 ,临床可广泛应用 Objective: To compare the efficacy and side effects of narisulb and nimotong in treating cerebral infarction. Methods: Seventy patients with cerebral infarction were randomly divided into two groups. Nilessu group 34 cases, with narisulla injection 10mg, intravenous, qd; nimotop group 36 cases, with nimotop injection 10mg, intravenous infusion, qd. Two groups of treatment are 2 weeks. Results: The effective rates of nalizox and nimotop on d14 after treatment were 88.24% and 83.33% respectively, and the adverse reaction rates were 14.7% and 13.88% respectively, with no significant difference (P> 0.05) 5). There was no significant difference in the improvement of function between the two groups (P> 0.05). Conclusion: Nilessu is a safe and effective drug for the treatment of cerebral infarction. It can be widely used clinically